ArticleGut and liver2020
Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study.
Article in Gut and liver, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study.The Korean journal of internal medicine · 2023Trial
- 2025 KASL clinical practice guidelines for management of hepatitis C.Clinical and molecular hepatology · 2026Article
- Temporal Dynamics and Treatment Outcomes of Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Multicenter Retrospective Study from South Korea.Gut and liver · 2025Article
- Clinico-epidemiological Patterns, Risk Factors, and Seroprevalence of Hepatitis C in Patients Attending a Tertiary Care Center in North India.Annals of African medicine · 2025Article
- Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study.Gut and liver · 2025Article
- Observational
- [Incidence and Characteristics of Hepatitis C Virus in Busan Metropolitan City, Ulsan Metropolitan City, and Gyeongsangnam-do, Republic of Korea, 2018-2023].Jugan geon-gang gwa jilbyeong · 2025Article
- Autoantibody positivity in chronic hepatitis C pre- and post-direct-acting antiviral therapy: a prospective multicenter south Korean study.Translational gastroenterology and hepatology · 2025Article
- Hepatitis C Virus Seroprevalence in Persons Who Inject Drugs in Korea, 2012-2022: A Multicenter, Retrospective Study.Journal of Korean medical science · 2023Article
- The Incidence and Care Cascade of the Hepatitis C Virus in Korea.Gut and liver · 2023Article
- Prevalence, incidence, and outcomes of hepatitis E virus coinfection in patients with chronic hepatitis C.Scientific reports · 2023Article
- Liver Diseases in South Korea: A Pulse Check of the Public's Knowledge, Awareness, and Behaviors.Yonsei medical journal · 2022Article
- The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment.Gut and liver · 2022Article
- Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.The Korean journal of internal medicine · 2022Article
- A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.Clinical and molecular hepatology · 2022Article
- Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.Gut and liver · 2021Article
- Comorbidities and Prescribed Medications in Korean Patients with Chronic Hepatitis C: A Nationwide, Population-Based Study.Gut and liver · 2021Article
- Prognosis of hepatocellular carcinoma metastasizing to the oral cavity.Maxillofacial plastic and reconstructive surgery · 2021Article
- Epidemiology and treatment status of hepatitis C virus infection among people who have ever injected drugs in Korea: a prospective multicenter cohort study from 2007 to 2019 in comparison with non-PWID.Epidemiology and health · 2021Article
- A Survey of the Knowledge of and Testing Rate for Hepatitis C in the General Population in South Korea.Gut and liver · 2020Article
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: This study aimed to elucidate the epidemiological and clinical characteristics of chronic hepatitis C (CHC) patients in South Korea from 2007 to 2017 and to compare the treatment patterns between two periods before and after the first approval of direct-acting antivirals (DAA) in South Korea in 2015. Methods: This prospective, multicenter cohort enrolled 2,758 patients with hepatitis C virus (HCV) viremia at seven tertiary centers, and clinical data were prospectively collected with questionnaire surveys focused on lifetime risk factors related to HCV infection. Results: The HCV patients had a mean age of 57.3 years (50.8% male). Among them, 14.3% showed a positive history of transfusion before HCV screening and 5.6% reported intravenous drug use (IVDU), with significant differences in these risk factors between men and women. The proportions of patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) were 69.5%, 18.9%, and 11.5%, respectively. The mean alanine aminotransaminase level was within the upper normal limit at 49.9%, and the major genotypes were 1b (48.2%) and 2 (46.4%). The overall treatment rate was 53.8%, showing a rapid transition from interferon-based therapy to DAA therapy. In the post-DAA-approval era, the untreated group was older, had a higher prevalence of HCC, and had less education than the treated group. Conclusions: More than 90% of CHC patients were over 40 years old, the major genotypes were 1b and 2, and IVDU was observed in less than 6% of CHC patients. Approximately half of the patients underwent antiviral therapy even in the DAA era, showing an unmet need with regard to HCV elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.